Erica Bhatt

Erica Bhatt focuses on adjuvant HER2-targeted therapy optimization for patients with residual disease after neoadjuvant treatment. Her clinical research builds on the KATHERINE trial showing T-DM1 superiority over trastuzumab in residual disease settings. She has also studied extended adjuvant neratinib and the optimal duration of pertuzumab in the adjuvant setting. Her translational work examines biomarkers from residual disease that predict recurrence to guide intensification or de-escalation of adjuvant therapy.